Oral rehydration salt (ORS) is a glucose-based salt solution used in oral rehydration therapy to prevent or treat dehydration from diarrhea in individuals. In many developing countries, diarrhea is one of the most common causes of mortality in infants and the mortality can be reduced to a great extent using ORS. The prevalence of diarrhea in developed regions such as Europe is continuously decreasing. However, the demand for sports ORS preparations is constantly increasing for retaining and recovering water and salt loss due to heavy exercises. Moreover, unpredictable immigration in the European countries due to various natural and unsustainable conditions is expected to increase the demand for ORS. For instance, immigrants from developing countries such as Africa and Syria in Europe have almost doubled in 2015. Availability of different dosage forms can fulfill different demands from a variety of consumer. For instance, ORS tablet and liquid are used by sports persons and travelers, as they are more convenient and easier for consumption.
Europe oral rehydration salt (ORS) market was valued at USD 2,446.08 million in 2018, growing at a CAGR of 5.1% during the forecast period of 2019–2026.
Penetration of OTC products in many European developing countries is witnessing considerable growth. Additionally, increasing purchasing power, growing awareness among population regarding advantages of ORS, and rising availability of all forms of ORS are expected to fuel the ORS market growth. For instance, O.R.S from Clinova has started launching its product in different European countries.
Apart from this, increasing consumption of alcohol among the young population and gaining importance of ORS to handle hangover are likely to propel the ORS market growth in the coming years. Small countries with a lack of investment in the healthcare sector are expected to offer a lucrative opportunity for the ORS manufacturer. Moreover, the strong presence of the target customer base for various dosage forms is expected to fuel the market growth. For instance, many ORS tablet manufacturing companies in Europe are promoting ORS tablet for athletes.
For a better understanding of the Europe oral rehydration salt (ORS) market, we have segmented the market by type, and application.
By Type, the market is segmented into tablets, powder, capsules and others. Powder is accounting for the largest market share in the forecast period. To make essential drugs available through most appropriate technology and simplest way at an affordable price, United Nations International Children's Emergency Fund (UNICEF) and World Health Organization (WHO) are collectively emphasizing on producing ORS in powder form for diarrhea treatment. However, continuously reducing cases of diarrhea in European countries have shifted the focus of the manufacturers towards other ORS preparations used to replace water and salt losses due to heavy exercise.
In Europe oral rehydration salt (ORS) market, U.K is generating the highest revenue in the forecast period. Though Europe has a greater number of developed countries in the world, Diarrhea is still the leading cause of death in children younger than 5 years. Rapidly developing companies to offer ORS in order to lower the death count related to Diarrhea have driven the demand for ORS. Many companies are offering ORS in various forms such as powder, tablet, and liquid, these are used in various marketing strategies to spread awareness regarding ORS throughout the region.
Developing tourism industry is one of the factors driving the demand for ORS in this region. Liquid dosage form of ORS is more convenient for handling and consumption mostly for the person who is traveling. For instance, Clinova’s strategy of associating with sports teams or individuals is making a positive impact on the revenue. Furthermore, the rising practice of different kinds of sports activities such as football, athletics, cycling, etc. and growing awareness among population regarding Diarrhea induced death are boosting the demand in European countries.
Some of the prominent players in the market are KBI Kunststoffbeutel Produktions GmbH & Co. KG, Monico SPA, Gebro Pharma AG, Primmed B.V., Nutriset, Clinova Ltd, Sanofi S.A., and Otsuka Pharmaceutical Co.,Ltd.
Among all the prominent players, Sanofi held the highest market share in terms of ORS revenue in 2017, which was closely followed by Clinova Ltd and Otsuka Pharmaceutical Co., Ltd. Partnership, merger, acquisition, and product development were some of the key strategies adopted by most of the leading market players. Sanofi, one of the leading healthcare companies in the world, is known for its medical innovations and partnership with external specialists. Its diverse portfolio of healthcare solutions and a strong network representing 145 nationalities are the major strengths of the company. Furthermore, it focuses on innovative development to bring life-enhancing medicines and devices in the U.K. For instance, in 2011, the company invested approximately USD 57.5 million in research and development in the U.K. In consumer healthcare segment, it is one of the leading players. Dioralyte is one of the leading brands of ORS in Europe making it a leading company.